Canadian families managing Attention Deficit Hyperactivity Disorder (ADHD) have a new treatment option. Today, Shire, the global specialty biopharmaceutical company, announced the Canadian availability of VYVANSE (lisdexamfetamine dimesylate capsule), the first and only prodrug therapy approved for ADHD treatment in Canada.
ADHD National Survey
According to an Angus Reid survey of 301 parents with ADHD-diagnosed children, while symptom control during school hours is the single most important reason for medication, 25 per cent of parents report their child’s medication wears off before school ends at 4:00 p.m. Half (50%) say their current medication wears off before dinner time (6:00 p.m.) and 73 per cent report their child’s ADHD is a challenge between 6:00 and 9:00 p.m.
Other highlights from the national survey:
- 60 per cent of families felt their teacher treated their child differently as a result of their ADHD diagnosis
- 88 per cent of parents felt treating their child’s ADHD had a positive impact on their self-esteem
- 93 per cent of families were interested in learning about new treatment options for their child’s ADHD
- 71 per cent of ADHD families in Canada have chosen medication as part of their ADHD treatment plan
- 84 per cent of ADHD families say their child is easily distracted and experiences difficulty in sustaining attention during activities.
Based on patient survey feedback, consistent symptom control with no highs or lows (83 per cent) and consistent symptom control from one day to the next (81 per cent) are important characteristics when choosing a medication for their child.
“Consistent ADHD symptom control from one day to the next, with no highs and lows, is an ongoing challenge for our family,” said Lisa Doucette, mother of a six year-old diagnosed with ADHD.
“My child needs symptom control all day, every day, in order to reach his full potential and VYVANSE has helped us achieve our goals.”